https://scholars.lib.ntu.edu.tw/handle/123456789/627255
標題: | Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission | 作者: | FENG-MING TIEN CHENG-HONG TSAI Huang, Sheng-Chuan JIA-HAU LIU Chen, Chien-Yuan YUAN-YEH KUO Chuang, Yi-Kuang Tseng, Mei-Hsuan Peng, Yen-Ling Liu, Ming-Chih CHIA-WEN LIU Liao, Xiu-Wen LIANG-IN LIN Wu, Yu-Sin Hou, Mei-Fang SHANG-JU WU SZU-CHUN HSU BOR-SHENG KO WEN-CHIEN CHOU MING YAO HSIN-AN HOU JIH-LUH TANG HWEI-FANG TIEN |
關鍵字: | ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATION; 2017 EUROPEAN LEUKEMIANET; NPM1 MUTATION; RISK-STRATIFICATION; PROGNOSTIC IMPACT; ADULT PATIENTS; SURVIVAL; DNMT3A; LEVEL | 公開日期: | 一月-2022 | 出版社: | SPRINGERNATURE | 卷: | 57 | 期: | 1 | 起(迄)頁: | 95 | 來源出版物: | Bone marrow transplantation | 摘要: | The mutant burden of FLT3-ITD modulates its prognostic impact on patients with acute myeloid leukemia (AML). However, for patients with low allelic ratio (AR) FLT3-ITD (FLT3-ITDlow, AR < 0.5), clinical features, as well as genomic and transcriptomic profiles remain unclear, and evidence supporting allogeneic hematopoietic stem cell transplantation (allo-HSCT) in first complete remission (CR1) remains controversial. This study aimed to elucidate the genomic features, prognosis, and transplantation outcome of FLT3-ITDIow in AML patients with intermediate-risk cytogenetics. FLT3-ITDlow was associated with a negative enrichment of the leukemic stem cell signature, a marked enrichment of the RAS pathway, and with higher frequencies of RAS pathway mutations, different from those with FLT3-ITDhigh. Concurrent CEBPA double mutations were favorable prognostic factors, whereas MLL-PTD, and mutations in splicing factors were unfavorable prognostic factors in FLT3-ITDlow patients. Patients with FLT3-ITDlow had a shorter overall survival (OS) and event-free survival (EFS) than those with FLT3wt. Allo-HSCT in CR1 was associated with a significantly longer OS and EFS compared with postremission chemotherapy in patients with FLT3-ITDlow. In conclusion, FLT3-ITDlow is associated with different mutational and transcriptomic profiles compared with FLT3-ITDhigh. The presence of concomitant poor-risk mutations exert negative prognostic impacts in patients with FLT3-ITDlow, who markedly benefit from allo-HSCT in CR1. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/627255 | ISSN: | 0268-3369 | DOI: | 10.1038/s41409-021-01454-z |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。